We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

80 hedge funds and large institutions have $90.2M invested in Gyre Therapeutics in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 18 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

424% more call options, than puts

Call options by funds: $398K | Put options by funds: $76K

72% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 18

59% more capital invested

Capital invested by funds: $56.5M → $90.2M (+$33.6M)

20% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 15

3% more funds holding

Funds holding: 78 → 80 (+2)

0.11% more ownership

Funds ownership: 8.52% → 8.63% (+0.11%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
80
Holders Change
+2
Holders Change %
+2.56%
% of All Funds
1.42%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
31
Reduced
18
Closed
15
Calls
$398K
Puts
$76K
Net Calls
+$322K
Net Calls Change
+$17K

Top Buyers

1
Verition Fund Management
Verition Fund Management
Connecticut
+$1.74M
2
OM
Opaleye Management
Massachusetts
+$859K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$803K
4
State Street
State Street
Massachusetts
+$555K
5
RJA
Raymond James & Associates
Florida
+$553K

Top Sellers

1
SCM
Stonepine Capital Management
Oregon
-$3.33M
2
Millennium Management
Millennium Management
New York
-$1.54M
3
PM
Prosight Management
Texas
-$1.3M
4
ACP
Acuta Capital Partners
California
-$811K
5
CCM
CAAS Capital Management
New York
-$670K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$11.8M +$252K +5,811 +2%
ACP
2
Acuta Capital Partners
California
$8.57M -$811K -18,720 -9%
BlackRock
3
BlackRock
New York
$8.5M +$409K +9,454 +6%
Vanguard Group
4
Vanguard Group
Pennsylvania
$6.2M +$369K +8,530 +7%
SCM
5
Stonepine Capital Management
Oregon
$5.26M -$3.33M -76,928 -41%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$4.99M +$59.9K +1,384 +1%
2L
7
22NW LP
Washington
$4.87M – – –
Millennium Management
8
Millennium Management
New York
$4.32M -$1.54M -35,467 -28%
ACM
9
AIGH Capital Management
Maryland
$2.66M +$2.43M +56,139 New
Two Sigma Advisers
10
Two Sigma Advisers
New York
$2.1M +$236K +5,440 +14%
State Street
11
State Street
Massachusetts
$2.08M +$555K +12,807 +41%
Two Sigma Investments
12
Two Sigma Investments
New York
$2.04M -$143K -3,312 -7%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$2M +$181K +4,174 +11%
ACM
14
Altium Capital Management
New York
$1.98M +$1.81M +41,833 New
Northern Trust
15
Northern Trust
Illinois
$1.94M -$101K -2,327 -5%
Verition Fund Management
16
Verition Fund Management
Connecticut
$1.91M +$1.74M +40,251 New
Goldman Sachs
17
Goldman Sachs
New York
$1.7M +$39.8K +920 +3%
PHP
18
Parkman Healthcare Partners
Connecticut
$1.19M -$112K -2,576 -9%
SCM
19
Sio Capital Management
New York
$1.19M -$57.7K -1,333 -5%
RJA
20
Raymond James & Associates
Florida
$1.07M +$553K +12,762 +131%
OM
21
Opaleye Management
Massachusetts
$939K +$859K +19,840 New
Renaissance Technologies
22
Renaissance Technologies
New York
$918K -$609K -14,066 -42%
Bank of Montreal
23
Bank of Montreal
Ontario, Canada
$904K +$803K +18,545 +13,636%
MHS
24
M Holdings Securities
Oregon
$806K +$1.17K +27 +0.2%
WVP
25
Worth Venture Partners
New Jersey
$627K -$166K -3,824 -22%
1
2 3 4

GYRE Hedge Fund Activity: Q4 2020 in Review

80 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2020, worth a combined $90.2M — up 59% from $56.5M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new GYRE positions and 15 closed out — a net gain of 3 holders — while 31 added to existing stakes and 18 trimmed.

The largest buyer was Verition Fund Management, opening a new position worth an estimated $1.74M. The largest seller was Stonepine Capital Management, cutting an estimated $3.33M.

  • 80 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2020, up from 78 in Q3 2020.
  • Funds reported $90.2M of Gyre Therapeutics stock for Q4 2020, up 59% quarter-over-quarter.
  • 18 funds opened new Gyre Therapeutics positions in Q4 2020 and 15 closed out, a net change of +3 holders.
  • The largest Gyre Therapeutics buyer in Q4 2020 was Verition Fund Management, an estimated $1.74M added.
  • The largest Gyre Therapeutics seller in Q4 2020 was Stonepine Capital Management, an estimated $3.33M sold.

Based on aggregated 13F filings for Q4 2020.